Kenvue says Tylenol is safe, but stock hits record low ahead of Trump speech

Kenvue Inc. (KVUE) shares plummeted 6.6% to a record low Monday amid investor anxiety over an imminent announcement by President Trump, expected to reveal scientific findings linking acetaminophen use during pregnancy to autism. Despite Kenvue's firm stance that independent science shows no such connection and that Tylenol remains the safest pain reliever for pregnant women, the high-profile nature of the potential disclosure fueled significant market concern, making KVUE the leading decliner on the S&P 500.

Analysis

Kenvue Inc. (KVUE) shares experienced a significant sell-off, declining 6.6% to reach a record low since its May 2023 separation from Johnson & Johnson. The sharp drop, which positioned the stock as the S&P 500's leading decliner, is directly attributable to investor apprehension over an imminent announcement by President Trump. This announcement is expected to publicize findings that purportedly link acetaminophen, the active ingredient in Kenvue's flagship Tylenol product, with autism in children following use during pregnancy. While the concern is not entirely new, with similar reports surfacing earlier in the month, the direct involvement of the President has amplified market fears and injected significant headline risk. In response, Kenvue has strongly refuted the expected claims, stating that independent scientific evidence does not support a causal link and reaffirming that acetaminophen is the safest pain-relief option for pregnant women. The market is currently pricing in a worst-case scenario driven by political and potential litigation risk, creating a clear conflict between the company's science-based defense and the potential for significant reputational and financial damage from a high-profile government-backed announcement.

Key Decisions for Investors

• Investors should brace for continued high volatility in KVUE, as the stock's performance is currently tethered to an event-driven political catalyst, not just company fundamentals.
• The core investment thesis now hinges on a binary outcome: the stock may see a sharp rebound if the scientific community refutes the administration's claims, or it could face prolonged pressure from litigation and consumer backlash if the report gains traction.
• Beyond the immediate stock price reaction, monitor for statements from medical associations and regulatory bodies, as their response will be critical in determining the long-term impact on Tylenol's brand equity and Kenvue's potential legal liabilities.